About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 72847 record(s)
Req # A-2023-000733
The initial cover letter and any other document indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-08-17 for the medicinal…Organization: Health Canada
August 2024
Req # A-2023-000897
The application by Benoit Labre House to operate a supervised consumption site, along with any subsequent correspondence, complementary document, appendix, and the documents analyzing the application.Organization: Health Canada
August 2024
Req # A-2023-001138
With respect SUMMARY MONTHLY SAFETY REPORT #7. The date when this report was received; the date when the review was completed and by whom including expertise/specialty; findings including: newly identified signals, both validated and invalidated, as…Organization: Health Canada
August 2024
Req # A-2023-001242
All documents and correspondence which the rapid test supplier BTNX, Inc., submitted to Health Canada as it applied for approval to sell the COVID-19 antigen test with the device identifiers COV-19CHC, COV-19CHC1, COV-19CHC2, COV-19CHC5, COV-19CHC25.Organization: Health Canada
August 2024
Req # A-2023-001300
Correspondence relating to any abbreviated new drug submission (ANDS) filed since January 1, 2023 where the medicinal ingredient is estradiol alone and the product’s indications include the treatment of postmenopausal moderate to severe dyspareunia.Organization: Health Canada
August 2024
Req # A-2023-001318
Data regarding the issuance of an No Objection Letter (NOL) on 2021-10-16 Notifiable Change (NC) # 257449 regarding changes to the drug manufacturing process of Comirnaty.Organization: Health Canada
August 2024
Req # A-2023-001324
The Product Information Template: Regulatory Enrollment Process (the equivalent of Section #67 of the previous Health Canada (HC)/Sante Canda (SC)-3011 Drug Submission Application Form) for the Mesalazine Abbreviated New Drug Submission (ANDS),…Organization: Health Canada
August 2024
Req # A-2023-001326
Rrecords containing information regarding the mock-ups of every label to be used in connection with the Mesalazine Abbreviated New Drug Submission (ANDS).Organization: Health Canada
August 2024
Req # A-2023-001327
The most recent Certified Product Information Document (CPID) submitted for the Mesalazine Abbreviated New Drug Submission (ANDS).Organization: Health Canada
August 2024
Req # A-2023-001328
The most recent Module 2.3: Quality Overall Summary (QOS) submitted by the sponsor for the Mesalazine Abbreviated New Drug Submission (ANDS).Organization: Health Canada
August 2024